Halozyme Therapeutics, Inc. Earnings

Halozyme Therapeutics, Inc.’s revenue jumped 35.22% since last year same period to $264.86Mn in the Q1 2025. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated -11.12% fall in its revenue since last 3-months.

Halozyme Therapeutics, Inc.’s net profit jumped 53.72% since last year same period to $118.1Mn in the Q1 2025. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated -13.81% fall in its net profits since last 3-months.

Halozyme Therapeutics, Inc.’s net profit margin jumped 13.69% since last year same period to 44.59% in the Q1 2025. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated -3.02% fall in its net profit margins since last 3-months.

Halozyme Therapeutics, Inc.’s price-to-earnings ratio after this Q1 2025 earnings stands at 14.36.

Halozyme Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at 1.21 - a 24.49% jump from last quarter’s estimates.

Halozyme Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at 1.21.

Halozyme Therapeutics, Inc.’s earning per share (EPS) fell -100% since last year same period to 0 in the Q2 2025. This indicates that the Halozyme Therapeutics, Inc. has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.